Morgan Stanley
ABVX

Morgan Stanley’s Abivax ABVX Stock Holding History

Morgan Stanley’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191M Sell
1,432,185
-272,773
-16% -$30.9M 0.01% 1076
2026
Q1 		$190M Sell
1,704,958
-1,447,036
-46% -$171M 0.01% 984
2025
Q4 		$425M Buy
3,151,994
+1,681,277
+114% +$183M 0.03% 589
2025
Q3 		$125M Buy
1,470,717
+995,437
+209% +$61M 0.01% 1227
2025
Q2 		$3.64M Sell
475,280
-21,873
-4% -$143K ﹤0.01% 4317
2025
Q1 		$3.11M Buy
497,153
+17,827
+4% +$121K ﹤0.01% 4303
2024
Q4 		$3.51M Sell
479,326
-25,426
-5% -$234K ﹤0.01% 4289
2024
Q3 		$5.81M Sell
504,752
-58,801
-10% -$705K ﹤0.01% 3856
2024
Q2 		$7.45M Sell
563,553
-29,902
-5% -$428K ﹤0.01% 3560
2024
Q1 		$8.49M Buy
593,455
+165,506
+39% +$2.13M ﹤0.01% 3479
2023
Q4 		$4.58M Buy
+427,949
New +$4.36M ﹤0.01% 3992

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Morgan Stanley's ABVX Position: Q2 2026 in Review

Morgan Stanley reduced its Abivax (ABVX) stake by 16% in Q2 2026, selling an estimated $30.9M and leaving 1,432,185 shares worth $191M. The position accounts for 0.01% of the portfolio, ranked #1076.

Morgan Stanley first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $425M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Morgan Stanley held 1,432,185 shares of Abivax worth $191M as of Q2 2026.
  • Morgan Stanley sold 272,773 Abivax shares in Q2 2026, an estimated $30.9M.
  • Abivax made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1076 holding.
  • Morgan Stanley first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • Morgan Stanley's Abivax position peaked at $425M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.